Cover |
Mar. 27, 2026 |
|---|---|
| Entity Addresses [Line Items] | |
| Document Type | POS AM |
| Amendment Flag | true |
| Amendment Description | On June 13, 2023, Biodexa Pharmaceuticals PLC, or the Company, filed a registration statement with the Securities and Exchange Commission, or the SEC, on Form F-1 (File No. 333-272693), or the Registration Statement. The Registration Statement was initially declared effective by the SEC on June 28, 2023, and originally covered a resale by the selling shareholders named in the Registration Statement, or the Selling Shareholders, of up to an aggregate of 280,217,300 ordinary shares, nominal value £0.000001 per share, or the Ordinary Shares, of the Company, represented by 2,802 American Depositary Shares, or the Depositary Shares, consisting of (1) 166,017,300 Ordinary Shares represented by 1,660 Depositary Shares, issuable upon the exercise of Series C warrants, (2) 109,800,000 Ordinary Shares represented by 1,098 Depositary Shares issuable upon the exercise of Series D warrants, and (3) 4,400,000 Ordinary Shares represented by 44 Depositary Shares issuable upon the exercise of placement agent warrants issued in the offering. On April 30, 2024, the Company filed Post-Effective Amendment No. 1 to Form F-1, or Post-Effective Amendment No. 1, which was subsequently declared effective by the SEC on May 2, 2024. Post-Effective Amendment No. 1 was filed by the Company to, among other things, update the Registration Statement to include information (i) contained in the Company’s Annual Report on Form 20-F for the fiscal year ended December 31, 2023, and (ii) regarding the Selling Shareholders named in the prospectus. On November 17, 2025, the Company filed Post-Effective Amendment No. 2 to Form F-1, or Post-Effective Amendment No. 2, which was subsequently declared effective by the SEC on November 21, 2025. Post-Effective Amendment No. 2 was filed by the Company to, among other things, update the Registration Statement to include information (i) contained in the Company’s Annual Report on Form 20-F for the fiscal year ended December 31, 2024, and (ii) regarding the Selling Shareholders named in the prospectus. This Post-Effective Amendment No. 3 to Form F-1, or Post-Effective Amendment No. 3, is being filed to among other things, update the Registration Statement to include information (i) contained in the Company’s Annual Report on Form 20-F for the fiscal year ended December 31, 2025, and (ii) regarding the Selling Shareholders named in the prospectus. The information included in this filing updates the Registration Statement and the prospectus contained therein. No additional securities are being registered under this Post-Effective Amendment No. 3. Accordingly, this Post-Effective Amendment No. 3 concerns only the offer and sale of Ordinary Shares represented by Depositary Shares issuable from time to time upon exercise of such warrants that remain unexercised. All applicable registration fees were paid at the time of the original filing of the Registration Statement. |
| Entity Registrant Name | Biodexa Pharmaceuticals PLC |
| Entity Central Index Key | 0001643918 |
| Entity Incorporation, State or Country Code | D5 |
| Entity Address, Address Line One | 1 Caspian Point |
| Entity Address, Address Line Two | Caspian Way |
| Entity Address, City or Town | Cardiff |
| Entity Address, Postal Zip Code | CF10 4DQ |
| Country Region | +44 |
| City Area Code | 29 |
| Local Phone Number | 20480 180 |
| Entity Filer Category | Non-accelerated Filer |
| Entity Emerging Growth Company | false |
| Document Creation Date | Mar. 27, 2026 |
| Business Contact [Member] | |
| Entity Addresses [Line Items] | |
| Entity Address, Address Line One | 850 Library Ave. |
| Entity Address, Address Line Two | Suite 204 |
| Entity Address, City or Town | Newark |
| Entity Address, State or Province | DE |
| Entity Address, Postal Zip Code | 19711 |
| City Area Code | 302 |
| Local Phone Number | 738-6680 |
| Contact Personnel Name | Donald J. Puglisi |